Noteworthy - Pharmaceutical Executive

ADVERTISEMENT

Noteworthy

Ireland: In Business for Biopharm

November 25, 2014

Despite recent changes in corporate tax law, Ireland remains an attractive partner in the development and manufacture of biopharmaceuticals, writes Rory Mullen of IDA Ireland.

Health 2.0 2014: Infrastructure Gets Sexy, HCP Apps Steal the Show

November 13, 2014

Two of the industry's most influential conferences occurred within weeks of each other this autumn – TEDMED and Health 2.0. Bill Drummy reviews both events.

Medicare Part B Data: Approach with Care

November 12, 2014

CMS's Part B data release has increased transparency but has also resulted in potentially misplaced scrutiny of high-billing doctors. Ben Scher, Kathleen Twigg, and Andrew Huson take a closer look.

Europe Edges Toward New HTA Understanding

November 19, 2014

The European Union is moving ahead, in its own slightly crabwise fashion, with its attempts to work out what healthcare budgets should be used for. Reflector reports.

Dane in America: Novo Nordisk's Jesper Hoiland

November 3, 2014

Novo Nordisk's Senior VP for North America, Jesper Hoiland, discusses his first year on the job at Novo's regional HQ in Princeton, NJ, including an unsettling initial encounter with PBM medicines gatekeepers.

Closing Gaps in the Supply Chain

November 1, 2014

Cynthia Challener reports on the progress of the supply chain security and quality group, the Rx-360 Consortium, five years on from its establishment.

Industry Growth Slows in Brazil

November 1, 2014

The Brazilian economy is being impacted by internal and external factors, and forecast figures are being quickly revised downwards. Hellen Berger reports.

Pharma Science: It's Hard

November 1, 2014

Amid a resurgence in drug development for hard-to-treat conditions, the bigger question is whether the times are as good for the industry tasked with rendering basic science into therapeutically effective medicines.

EMA Clinical Data Disclosure Plan Under Fire

October 27, 2014

The EMA might have expected that the publication of its plan for proactive release of clinical reports would receive a warm welcome. But, Reflector writes, it is far from a roaring success.

ADVERTISEMENT

Click here